BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 22078148)

  • 1. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
    Karatayli E; Karatayli SC; Cinar K; Gokahmetoglu S; Güven K; Idilman R; Yurdaydin C; Bozdayi AM
    J Clin Virol; 2012 Feb; 53(2):130-4. PubMed ID: 22078148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
    Karatayli E; Idilman R; Karatayli SC; Cevik E; Yakut M; Seven G; Kabaçam G; Bozdayi AM; Yurdaydin C
    Antivir Ther; 2013; 18(1):77-85. PubMed ID: 22878399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
    Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
    Cho SW; Koh KH; Cheong JY; Lee MH; Hong SP; Yoo WD; Kim SO
    J Viral Hepat; 2010 Mar; 17(3):171-7. PubMed ID: 19678894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
    Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
    J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
    J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
    J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
    Yim HJ; Lee HJ; Suh SJ; Seo YS; Kim CW; Lee CD; Park SH; Lee MS; Park CK; Chae HB; Kim MY; Baik SK; Kim YS; Kim JH; Lee JI; Lee JW; Hong SP; Um SH
    Intervirology; 2014; 57(5):239-47. PubMed ID: 24993731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
    Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
    J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
    Yang S; Xing H; Wang Q; Wang X; Liu S; Cheng J
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():24. PubMed ID: 27079793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
    Liu Y; Wang C; Zhong Y; Chen L; Li X; Ji D; Wang H; Xin S; Zoulim F; Xu D
    Antivir Ther; 2010; 15(8):1185-90. PubMed ID: 21149926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.